BACKGROUND: This study was performed to collect prospective safety and effectiveness data from a tissue-engineered heart valve implanted for reconstruction of the right ventricular outflow tract during the Ross operation. METHODS: From May 2000 until June 2002, 11 consecutive patients, mean age 39.6 ± 10.3 years, received a tissue-engineered heart valve (additive and logistic European System for Cardiac Operative Risk Evaluation, respectively, 3.3 ± 1.3 and 2.8% ± 1.4%). Two to four weeks prior to the Ross operation a piece of forearm vein or saphenous vein was harvested to isolate, characterize, and expand endothelial cells. A cryopreserved pulmonary allograft was decellularized, coated, and seeded with autologous vascular endothelial cells, using a specially developed bioreactor. Cell seeding density was 1.1 × 10(5) ± 0.5 × 10(5) cells/cm(2) with a viability of 93.2% ± 2.1%. RESULTS: All patients survived surgery. Postoperatively no fever of unknown origin was evident. Currently all patients are in New York Heart Association class I. Evaluation of the tissue-engineered heart valve by transthoracic echocardiography showed a mean pressure gradient of 5.4 ± 2.0 mm Hg at 10 years. Multislice computed tomography showed no calcification up to 10 years. CONCLUSIONS: Tissue-engineered heart valves showed excellent hemodynamic performance and may prevent degeneration during long-term follow-up.
BACKGROUND: This study was performed to collect prospective safety and effectiveness data from a tissue-engineered heart valve implanted for reconstruction of the right ventricular outflow tract during the Ross operation. METHODS: From May 2000 until June 2002, 11 consecutive patients, mean age 39.6 ± 10.3 years, received a tissue-engineered heart valve (additive and logistic European System for Cardiac Operative Risk Evaluation, respectively, 3.3 ± 1.3 and 2.8% ± 1.4%). Two to four weeks prior to the Ross operation a piece of forearm vein or saphenous vein was harvested to isolate, characterize, and expand endothelial cells. A cryopreserved pulmonary allograft was decellularized, coated, and seeded with autologous vascular endothelial cells, using a specially developed bioreactor. Cell seeding density was 1.1 × 10(5) ± 0.5 × 10(5) cells/cm(2) with a viability of 93.2% ± 2.1%. RESULTS: All patients survived surgery. Postoperatively no fever of unknown origin was evident. Currently all patients are in New York Heart Association class I. Evaluation of the tissue-engineered heart valve by transthoracic echocardiography showed a mean pressure gradient of 5.4 ± 2.0 mm Hg at 10 years. Multislice computed tomography showed no calcification up to 10 years. CONCLUSIONS: Tissue-engineered heart valves showed excellent hemodynamic performance and may prevent degeneration during long-term follow-up.
Authors: Petra E Dijkman; Emanuela S Fioretta; Laura Frese; Francesco S Pasqualini; Simon P Hoerstrup Journal: Transfus Med Hemother Date: 2016-07-26 Impact factor: 3.747
Authors: Rebekah A Neal; Aurélie Jean; Hyoungshin Park; Patrick B Wu; James Hsiao; George C Engelmayr; Robert Langer; Lisa E Freed Journal: Tissue Eng Part A Date: 2012-11-28 Impact factor: 3.845
Authors: Igor Tudorache; Alex Calistru; Hassina Baraki; Tanja Meyer; Klaus Höffler; Samir Sarikouch; Christopher Bara; Adelheid Görler; Dagmar Hartung; Andres Hilfiker; Axel Haverich; Serghei Cebotari Journal: Tissue Eng Part A Date: 2013-04-26 Impact factor: 3.845
Authors: Emanuela S Fioretta; Sarah E Motta; Valentina Lintas; Sandra Loerakker; Kevin K Parker; Frank P T Baaijens; Volkmar Falk; Simon P Hoerstrup; Maximilian Y Emmert Journal: Nat Rev Cardiol Date: 2020-09-09 Impact factor: 32.419
Authors: Iyore A James; Tai Yi; Shuhei Tara; Cameron A Best; Alexander J Stuber; Kejal V Shah; Blair F Austin; Tadahisa Sugiura; Yong-Ung Lee; Joy Lincoln; Aaron J Trask; Toshiharu Shinoka; Christopher K Breuer Journal: Tissue Eng Part C Methods Date: 2015-05-29 Impact factor: 3.056